1. Key Insights 2. Executive Summary 3. Hemophilia A: Market Overview at a Glance 3.1. Total Market Share (%) Distribution of Hemophilia A in 2017 3.2. Total Market Share (%) Distribution of Hemophilia A in 2030 4. Hemophilia A: Disease Background and Overview 4.1. Introduction 4.1.1. Sign and Symptoms of Hemophilia A 4.1.2. Inheritance Pattern of Hemophilia A 4.1.3. Molecular Pathogenesis of Hemophilia A 4.1.4. Pathophysiology of Hemophilia A 4.1.5. Risk Factors of Hemophilia A 4.2. Diagnosis of Hemophilia A 4.2.1. Establishing the Diagnosis 4.2.2. Molecular Genetic Testing 4.2.3. Screening Tests 4.2.4. Clotting Factor Tests 4.2.5. Inhibitor Testing 5. Epidemiology and Patient Population 5.1. Epidemiology Key Findings 5.2. Assumptions and Rationale: 7MM 5.3. Epidemiology Scenario: 7MM 5.3.1. Total Prevalence of Hemophilia A in the 7MM 5.3.2. Diagnosed and Treated Prevalent Population of Hemophilia A in the 7MM 5.3.3. Severity- Specific Prevalence of Hemophilia A in the 7MM 5.3.4. Prevalence of Hemophilia A with or without Inhibitors the 7MM 6. United States Epidemiology 6.1. Total Prevalence of Hemophilia A in the United States 6.2. Diagnosed and Treated Prevalent Population of Hemophilia A in the United States 6.3. Severity- Specific Prevalence of Hemophilia A in the United States 6.4. Prevalence of Hemophilia A with Inhibitors and Without Inhibitors in the United States 7. EU-5 Country-wise Epidemiology 7.1. Germany Epidemiology 7.1.1. Total Prevalence of Hemophilia A in Germany 7.1.2. Diagnosed and Treated Prevalent Population of Hemophilia A in Germany 7.1.3. Severity- Specific Prevalence of Hemophilia A in Germany 7.1.4. Prevalence of Hemophilia A with or without Inhibitors in Germany 7.2. France Epidemiology 7.2.1. Total Prevalence of Hemophilia A in France 7.2.2. Diagnosed and Treated Prevalent Population of Hemophilia A in France 7.2.3. Severity- Specific Prevalence of Hemophilia A in France 7.2.4. Prevalence of Hemophilia A with or without Inhibitors in France 7.3. Italy Epidemiology 7.3.1. Total Prevalence of Hemophilia A and B in Italy 7.3.2. Diagnosed and Treated Prevalent Population of Hemophilia A in Italy 7.3.3. Severity-Specific Prevalence of Hemophilia A in Italy 7.3.4. Prevalence of Hemophilia A with or without Inhibitors in Italy 7.4. Spain Epidemiology 7.4.1. Total Prevalence of Hemophilia A in Spain 7.4.2. Diagnosed Prevalent Population of Hemophilia A in Spain 7.4.3. Severity- Specific Prevalence of Hemophilia A in Spain 7.4.4. Prevalence of Hemophilia A with Inhibitors or Without-Inhibitors in Spain 7.5. United Kingdom Epidemiology 7.5.1. Total Prevalence of Hemophilia A in the United Kingdom 7.5.2. Diagnosed and Treated Prevalent Population of Hemophilia A in the United Kingdom 7.5.3. Severity- Specific Prevalence of Hemophilia A in the United Kingdom 7.5.4. Prevalence of Hemophilia A with Inhibitors or Non-Inhibitors in the United Kingdom 8. Japan Epidemiology 8.1. Total Prevalence of Hemophilia A in Japan 8.2. Diagnosed and Treated Prevalent Population of Hemophilia A in Japan 8.3. Severity- Specific Prevalence of Hemophilia A in Japan 8.4. Prevalence of Hemophilia A with Inhibitors and Without Inhibitors in Japan 9. Treatment Algorithm, Current Treatment, and Medical Practices 9.1. Treatment and Management of Hemophilia A 9.1.1. Algorithm for treatment of Hemophilia A 9.2. Principles of care of Hemophilia A 9.3. Clotting Factors Concentrates 9.4. Prevention of Primary Manifestations 9.5. Prevention of Secondary Complications 9.6. Agents/Circumstances to Avoid 9.7. Inhibitors 9.8. Pregnancy Management 10. Unmet Needs 11. Marketed Products 11.1. List of Marketed Products in the 7MM 11.2. Esperoct (N8-GP; Turoctocog alfa pegol): Novo Nordisk 11.2.1. Product Description 11.2.2. Regulatory Milestones 11.2.3. Other Developmental Activities 11.2.4. Pivotal Clinical Trials 11.3. Jivi (formerly BAY94-9027): Bayer 11.3.1. Drug Description 11.3.2. Regulatory Milestones 11.3.3. Other Developmental Activities 11.3.4. Pivotal Clinical Trial 11.3.5. Summary of Pivotal Clinical Trial 11.4. Hemlibra (Emicizumab-kxwh): Chugai/ Genentech/Roche 11.4.1. Product Description 11.4.2. Regulatory Milestones 11.4.3. Other Developmental Activities 11.4.4. Pivotal Clinical Trials 11.5. Wilate: Octapharma 11.5.1. Product Description 11.5.2. Regulatory Milestones 11.5.3. Pivotal Clinical Trials 11.6. Adynovate (Adynovi; BAX 855): Takeda 11.6.1. Product Description 11.6.2. Regulatory Milestones 11.6.3. Other Developmental Activities 11.6.4. Pivotal Clinical Trials 11.7. Eloctate [Antihemophilic Factor (Recombinant), Fc Fusion Protein; Elocta (efmoroctocog alfa)]: Sanofi/Sobi 11.7.1. Product Description 11.7.2. Regulatory Milestones 11.7.3. Other Developmental Activities 11.7.4. Pivotal Clinical Trials 11.8. Afstyla (Lonoctocog alfa): CSL Behring 11.8.1. Product Description 11.8.2. Regulatory Milestones 11.8.3. Other Developmental Activities 11.8.4. Pivotal Clinical Trials 11.9. Kovaltry (BAY 81-8973): Bayer 11.9.1. Product Description 11.9.2. Regulatory Milestones 11.9.3. Other Developmental Activities 11.9.4. Pivotal Clinical Trials 11.10. Nuwiq (simoctocog alfa): Octapharma 11.10.1. Product Description 11.10.2. Regulatory Milestones 11.10.3. Pivotal Clinical Trials 11.11. NovoEight (Turoctocog alfa): Novo Nordisk 11.11.1. Product Description 11.11.2. Regulatory Milestones 11.11.3. Other Developmental Activities 11.11.4. Pivotal Clinical Trials 11.12. Obizur: Takeda 11.12.1. Product Description 11.12.2. Regulatory Milestones 11.12.3. Other Developmental Activities 11.12.4. Pivotal Clinical Trials 11.13. Kogenate FS (octocog alfa): Bayer 11.13.1. Product Description 11.13.2. Regulatory Milestones 11.13.3. Pivotal Clinical Trials 11.14. Xyntha (ReFacto AF): Pfizer 11.14.1. Product Description 11.14.2. Regulatory Milestones 11.14.3. Other Developmental Activities 11.14.4. Pivotal Clinical Trials 11.15. Feiba: Takeda 11.15.1. Product Description 11.15.2. Regulatory Milestones 11.15.3. Other Developmental Activities 11.15.4. Pivotal Clinical Trials 12. Emerging Therapies 12.1. Key Cross 12.2. Valoctocogene Roxaparvovec (BMN 270): BioMarin Pharmaceutical 12.2.1. Product Description 12.2.2. Other Developmental Activities 12.2.3. Clinical Development 12.2.4. Safety and Efficacy 12.3. LR769: HEMA Biologics/LFB Biotechnologies 12.3.1. Product Description 12.3.2. Other Developmental Activities 12.3.3. Clinical Development 12.3.4. Safety and Efficacy 12.4. Concizumab (NN7415): Novo Nordisk 12.4.1. Product Description 12.4.2. Other Developmental Activities 12.4.3. Clinical Development 12.4.4. Safety and Efficacy 12.5. Fitusiran (ALN-AT3, SAR-439774): Sanofi Genzyme/ Alnylam Pharmaceuticals 12.5.1. Product Description 12.5.2. Other Developmental Activities 12.5.3. Clinical Development 12.5.4. Safety and Efficacy 12.6. BIVV001 (rFVIIIFc-VWF-XTEN): Sanofi 12.6.1. Product Description 12.6.2. Other Developmental Activities 12.6.3. Clinical Development 12.6.4. Safety and Efficacy 12.7. Marstacimab (PF-06741086): Pfizer 12.7.1. Product Description 12.7.2. Other Developmental Activities 12.7.3. Clinical Development 12.7.4. Safety and Efficacy 12.8. Marzeptacog alfa (Activated): Catalyst Biosciences 12.8.1. Product Description 12.8.2. Other Developmental Activities 12.8.3. Clinical Development 12.8.4. Safety and Efficacy 12.9. OPK88005: OPKO Biologics 12.9.1. Product Description 12.9.2. Other Developmental Activities 12.9.3. Clinical Development 12.10. SPK-8011: Spark Therapeutics 12.10.1. Product Description 12.10.2. Other Developmental Activities 12.10.3. Clinical Development 12.10.4. Safety and Efficacy 13. Hemophilia A: Seven Major Market Analysis 13.1. Key Findings 13.2. Market Size of Hemophilia A in 7MM 13.3. Market Size of Hemophilia A by Therapies in the 7MM 14. 7MM: Market Outlook 15. United States: Market Size 15.1. Total Market size of Hemophilia A in the United States 15.2. Market Size of Hemophilia A by Therapies in the US 16. EU-5 countries: Market Size and Outlook 16.1. Germany Market Size 16.1.1. Total Market size of Hemophilia A in Germany 16.1.2. Market Size of Hemophilia A by therapies in Germany 16.2. France Market Size 16.2.1. Total Market size of Hemophilia A in France 16.2.2. Market Size of Hemophilia A by therapies in France 16.3. Italy Market Size 16.3.1. Total Market size of Hemophilia A in Italy 16.3.2. Market Size of Hemophilia A by therapies in Italy 16.4. Spain Market Size 16.4.1. Total Market size of Hemophilia A in Spain 16.4.2. Market Size of Hemophilia A by therapies in Spain 16.5. United Kingdom Market Size 16.5.1. Total Market size of Hemophilia A in the United Kingdom 16.5.2. Market Size of Hemophilia A by therapies in the UK 17. Japan Market Outlook 17.1. Japan Market Size 17.1.1. Total Market size of Hemophilia A in Japan 17.1.2. Market Size of Hemophilia A by therapies in Japan 18. Market Drivers 19. Market Barriers 20. Appendix 20.1. Report Methodology 21. DelveInsight Capabilities 22. Disclaimer 23. About DelveInsight

Table 1 Summary of Hemophilia A Market, Epidemiology, and Key Events (2017–2030) Table 2 Approximate Frequency of Bleeding at Different Sites Table 3 Sites of Bleeding In Hemophilia Table 4 Levels of Factors in Hemophilia A Table 5 Summary of sources explored for the epidemiology of hemophilia A Table 6 Total Prevalence of HemophiliaA in the 7MM (2017–2030) Table 7 Diagnosed and Treated Prevalent Population of Hemophilia A in the 7MM (2017–2030) Table 8 Severity- Specific Prevalence of Hemophilia A in the 7MM (2017–2030) Table 9 Prevalence of Hemophilia A with or without Inhibitors the 7MM (2017–2030) Table 10 Total Prevalence of Hemophilia A in the United States (2017–2030) Table 11 Diagnosed and Treated Prevalent Population of Hemophilia A in the US (2017–2030) Table 12 Severity- Specific Prevalence of Hemophilia A in the US (2017–2030) Table 13 Prevalence of Hemophilia A with Inhibitors and Without Inhibitors in the United States (2017–2030) Table 14 Total Prevalence of Hemophilia A in Germany (2017–2030) Table 15 Diagnosed and Treated Prevalent Population of Hemophilia A in Germany (2017–2030) Table 16 Severity- Specific Prevalence of Hemophilia A in Germany (2017–2030) Table 17 Diagnosed Prevalence of Hemophilia A with or Non-Inhibitors in Germany (2017–2030) Table 18 Total Prevalence of Hemophilia A in France (2017–2030) Table 19 Diagnosed and Treated Prevalent Population of Hemophilia A in France (2017–2030) Table 20 Severity- Specific Prevalence of Hemophilia A in France (2017–2030) Table 21 Diagnosed Prevalence of Hemophilia A with or Non-Inhibitors in France (2017–2030) Table 22 Total Prevalence of Hemophilia A in Italy (2017–2030) Table 23 Diagnosed and Treated Prevalent Population of Hemophilia A in Italy (2017–2030) Table 24 Severity-Specific Diagnosed Prevalence of Hemophilia A in Italy (2017–2030) Table 25 Prevalence of Hemophilia A with or Non-Inhibitors in Italy (2017–2030) Table 26 Total Prevalence of Hemophilia A in the Spain (2017–2030) Table 27 Diagnosed and Treated Prevalent Population of Hemophilia A in Spain (2017–2030) Table 28 Severity-Specific Prevalence of Hemophilia A in Spain (2017–2030) Table 29 Diagnosed Prevalence of Hemophilia A with or Non-Inhibitors in Spain (2017–2030) Table 30 Total Prevalence of Hemophilia A and B in the United Kingdom (2017–2030) Table 31 Diagnosed and Treated Prevalent Population of Hemophilia A in the United Kingdom (2017–2030) Table 32 Severity-Specific Prevalence of Hemophilia A in the United Kingdom (2017–2030) Table 33 Prevalence of Hemophilia A with or Non-Inhibitors in the United Kingdom (2017–2030) Table 34 Total Prevalence of Hemophilia A in Japan (2017–2030) Table 35 Diagnosed and Treated Prevalent Population of Hemophilia A in Japan (2017–2030) Table 36 Severity- Specific Prevalence of Hemophilia A in Japan (2017–2030) Table 37 Prevalence of Hemophilia A with Inhibitors and Without Inhibitors in Japan (2017–2030) Table 38 Jivi, Clinical Trial Description, 2019 Table 39 Emerging Drugs key-Cross Table 40 Valoctocogene Roxaparvovec (BMN 270), Clinical Trial Description, 2019 Table 41 LR769 (Eptacogum Beta Activated), Clinical Trial Description, 2019 Table 42 Concizumab, Clinical Trial Description, 2019 Table 43 Fitusiran, Clinical Trial Description, 2019 Table 44 BIVV001, Clinical Trial Description, 2019 Table 45 Marstacimab (PF-06741086), Clinical Trial Description, 2019 Table 46 Marzeptacog alfa (Activated), Clinical Trial Description, 2019 Table 47 OPK88005, Clinical Trial Description, 2019 Table 48 SPK-8011 , Clinical Trial Description, 2019 Table 49 Market Size of Hemophilia A in the 7MM in USD Million (2017–2030) Table 50 The US Market Size of Hemophilia A in USD Million (2017–2030) Table 51 Market Size of Hemophilia A by therapies (Inhibitors), in the United States, in USD Million (2017–2030) Table 52 Market Size of Hemophilia A by therapies (Non-Inhibitors) in the United States, in USD Million (2017–2030) Table 53 Germany Market Size of Hemophilia A in USD Million (2017–2030) Table 54 Market Size of Hemophilia A by therapies (Inhibitors) in Germany, in USD Million (2017–2030) Table 55 Market Size of Hemophilia A by therapies (Non-Inhibitors) in France, in USD Million (2017–2030) Table 56 Market Size in USD Million (2017–2030) Table 57 Market Size of Hemophilia A by therapies (Inhibitors) in France, in USD Million (2017–2030) Table 58 Market Size of Hemophilia A by therapies (Non-Inhibitors) in France, in USD Million (2017–2030) Table 59 Market Size in USD Million (2017–2030) Table 60 Market Size of Hemophilia A by therapies (Inhibitors) in Italy, in USD Million (2017–2030) Table 61 Market Size of Hemophilia A by therapies (Non-Inhibitors) in Italy, in USD Million (2017–2030) Table 62 Market Size in USD Million (2017–2030) Table 63 Market Size of Hemophilia A by therapies (Inhibitors) in Spain, in USD Million (2017–2030) Table 64 Market Size of Hemophilia A by therapies (Non-Inhibitors) in the Spain, in USD Million (2017–2030) Table 65 Market Size in USD Million (2017–2030) Table 66 Market Size of Hemophilia A by therapies (Inhibitors) in the UK, in USD Million (2017–2030) Table 67 Market Size of Hemophilia A by therapies (Non-Inhibitors) in the UK, in USD Million (2017–2030) Table 68 Japan Market Size of Hemophilia A in USD Million (2017–2030) Table 69 Market Size of Hemophilia A by therapies (Inhibitors) in Japan, in USD Million (2017–2030) Table 70 Market Size of Hemophilia A by therapies (Non-Inhibitors) in Japan, in USD Million (2017–2030) Figure 1 Coagulation Cascade and the Effects of Recombinant Activated Factor Vll (rFVlla) Figure 2 Inheritance Pattern of Hemophilia A Figure 3 Established and Proposed Risk Factors for Inhibitor Development Figure 4 Screening Tests for Hemophilia A Figure 5 Total Prevalence of Hemophilia A in the 7MM (2017–2030) Figure 6 Diagnosed and Treated Prevalent Population of Hemophilia A in the 7MM (2017–2030) Figure 7 Total Prevalence of Hemophilia A in the 7MM (2017–2030) Figure 8 Prevalence of Hemophilia A with or without Inhibitors in the 7MM (2017–2030) Figure 9 Total Prevalent Population of Hemophilia A in the United States (2017–2030) Figure 10 Diagnosed and Treated Prevalent Population of Hemophilia A in the US (2017–2030) Figure 11 Severity- Specific Prevalence of Hemophilia A in the US (2017–2030) Figure 12 Prevalence of Hemophilia A with Inhibitors and Without Inhibitors in the United States (2017–2030) Figure 13 Total Prevalence of Hemophilia A in Germany (2017–2030) Figure 14 Diagnosed and treated Prevalent Population of Hemophilia A in Germany (2017–2030) Figure 15 Severity- Specific Prevalence of Hemophilia A in Germany (2017–2030) Figure 16 Prevalence of Hemophilia A with or Non-Inhibitors in Germany (2017–2030) Figure 17 Total Prevalence of Hemophilia A in France (2017–2030) Figure 18 Diagnosed and Treated Prevalent Population of Hemophilia A in France (2017–2030) Figure 19 Severity-Specific Prevalence of Hemophilia A in France (2017–2030) Figure 20 Diagnosed Prevalence of Hemophilia A with or Non-Inhibitors in France (2017–2030) Figure 21 Total Prevalence of Hemophilia A and B in Italy (2017–2030) Figure 22 Diagnosed and Treated Prevalent Population of Hemophilia A in Italy (2017–2030) Figure 23 Severity- Specific Prevalence of Hemophilia A in Italy (2017–2030) Figure 24 Prevalence of Hemophilia A with or Non-Inhibitors in Italy (2017–2030) Figure 25 Total Prevalence of Hemophilia A and B in Spain (2017–2030) Figure 26 Diagnosed Prevalent Population of Hemophilia A in Spain (2017–2030) Figure 27 Severity- Specific Prevalence of Hemophilia A in Spain (2017–2030) Figure 28 Prevalence of Hemophilia A with or Non-Inhibitors in Spain (2017–2030) Figure 29 Total Prevalence of Hemophilia A and B in the United Kingdom (2017–2030) Figure 30 Diagnosed and Treated Prevalent Population of Hemophilia A in the United Kingdom (2017–2030) Figure 31 Severity- Specific Prevalence of Hemophilia A in the United Kingdom (2017–2030) Figure 32 Prevalence of Hemophilia A with or Non-Inhibitors in the United Kingdom (2017–2030) Figure 33 Total Prevalent Population of Hemophilia A in Japan (2017–2030) Figure 34 Diagnosed and Treated Patient Population of Hemophilia A in Japan (2017–2030) Figure 35 Severity- Specific Prevalence of Hemophilia A in Japan (2017–2030) Figure 36 Prevalence of Hemophilia A with Inhibitors and Without Inhibitors in Japan (2017–2030) Figure 37 Treatment Algorithm for the patient with Hemophilia A Figure 38 Management Algorithm for the patient with Inhibitors Figure 39 Improvements in Hemophilia Therapy Figure 40 Unmet Needs of Hemophilia A Figure 41 Market Size of Hemophilia A in the 7MM in USD Million (2017–2030) Figure 42 Market Size of Hemophilia A by therapies (Inhibitors)in the 7MM, in USD Million (2017–2030) Figure 43 Market Size of Hemophilia A by therapies (Non-Inhibitors) in the 7MM, in USD Million (2017–2030) Figure 44 Market Size of Hemophilia A in the US, USD Millions (2017–2030) Figure 45 Market Size of Hemophilia A by therapies (Inhibitors) in the United States, in USD Million (2017–2030) Figure 46 Market Size of Hemophilia A by therapies (Non-Inhibitors) the United States, in USD Million (2017–2030) Figure 47 Market Size of Hemophilia A in Germany, USD Millions (2017–2030) Figure 48 Market Size of Hemophilia A by therapies (Inhibitors) in Germany, in USD Million (2017–2030) Figure 49 Market Size of Hemophilia A by therapies (Non-Inhibitors) in Germany, in USD Million (2017–2030) Figure 50 Market Size of Hemophilia A in France, USD Millions (2017–2030) Figure 51 Market Size of Hemophilia A by therapies (Inhibitors) in France, in USD Million (2017–2030) Figure 52 Market Size of Hemophilia A by therapies (Non-Inhibitors) in France, in USD Million (2017–2030) Figure 53 Market Size of Hemophilia A in Italy, USD Millions (2017–2030) Figure 54 Market Size of Hemophilia A by therapies (Inhibitors) in Italy, in USD Million (2017–2030) Figure 55 Market Size of Hemophilia A by therapies (Non-Inhibitors) in Italy, in USD Million (2017–2030) Figure 56 Market Size of Hemophilia A in Spain, USD Millions (2017–2030) Figure 57 Market Size of Hemophilia A by therapies (Inhibitors) in Spain, in USD Million (2017–2030) Figure 58 Market Size of Hemophilia A by therapies (Non-Inhibitors) in Spain, in USD Million (2017–2030) Figure 59 Market Size of Hemophilia A in the UK, USD Millions (2017–2030) Figure 60 Market Size of Hemophilia A by therapies (Inhibitors) in the UK, in USD Million (2017–2030) Figure 61 Market Size of Hemophilia A by therapies (Non-Inhibitors) in the UK, in USD Million (2017–2030) Figure 62 Market Size of Hemophilia A in Japan, USD Millions (2017–2030) Figure 63 Market Size of Hemophilia A by therapies (Inhibitors) in Japan, in USD Million (2017–2030) Figure 64 Market Size of Hemophilia A by therapies (Non-Inhibitors) in Japan, in USD Million (2017–2030) Figure 65 Market Drivers of Hemophilia A Figure 66 Market Barriers of Hemophilia A

1. Novo Nordisk 2. Shire 3. Sanofi 4. Bayer 5. Roche 6. Pfizer 7. Biomarin Pharmaceutical 8. Alnylam Pharmaceuticals 9. HEMA Biologics 10. LFB Biotechnologies 11. Catalyst Biosciences 12. Opko Biologics 13. Spark Therapeutics 14. Sangamo Therapeutics 15. ApcinteX Ltd